World’s largest mobile operator pledges not to collect licence fees on 5G contributions which reports say have generated nearly 1,000 patent applications
An in-depth analysis shows that the American medical device manufacturer may not gain much in terms of quantity from its $4 billion purchase, but that the British healthcare company’s IP assets will boost its peripheral interventional offerings
Days after announced trade truce, China’s government explains ‘social credit score’ consequences for IP infringers first floated three years ago. Penalties range from borrowing restrictions to air travel bans.
John LaBarre's move to a biotech start-up follows previous departures of Allen Lo and Jeremiah Chan to Facebook, and is further evidence of the narrowing IP strategy gap between high-tech and the life sciences
This year's event in Shanghai has now come to an end. It's been a great couple of days, including the IP Asia Elite Gala Dinner and Awards held last night
How Chinese courts will rule the patent world; Qualcomm's 5G licensing spree; don't jail trolls, says former supreme court judge; patent sales are on the up; plus a whole lot more from a wet, but spectacular, Shanghai Pudong
Your essential Sunday reading: a summary of all the stories posted on the IAM platform in the past week - as well as links to each one
“The patent market has fully stabilised and prices are rational,” said no one ever. During 2018 total dollars transacted in brokered deals increased while prices of single-asset deals have dropped significantly.
Boards and directors typically prioritise non-IP issues on the corporate agenda; however, legal requirements and market activities suggest that this might be a serious misstep.
Previous FRAND-related rulings indicate judges in China could set a global rate, would adopt the hard-edged non-discrimination obligation and would consider the parties' negotiation behaviours when reaching their decisions
There is not much time left to make nominations for the 2019 edition of IAM Strategy 300, our exclusive guide on the world's best IP strategists.
The pace of change in the life sciences industry is startling and is putting traditional IP management strategies under extreme pressure. It may be time for IP leaders to start looking to the tech industry experience for lessons in how to respond.
For over half a century Dolby Labs has worked hard to ensure that the company’s IP strategy is always aligned with its overall business goals. Its success in doing this teaches valuable lessons.
The USPTO director’s explicit rejection of the ‘troll’ narrative and the departure of key Congressional backers mean that big technology companies find themselves in the unusual position of not being in control of the US IP policy-making narrative.
A selection of key IP facts and figures, as reported by IAM and other sources.
